Aplastic Anemia Treatment Market Trends

Growth Drivers

• Increasing Awareness Campaigns for Aplastic Anemia and Blood Disorders by Public and Private Organizations - Aplastic anemia is a rare, yet potentially life-threatening condition. Through increasing public and private initiatives, more people are becoming aware of the condition and its complications. These initiatives are aimed at educating the general public about the symptoms and causes of aplastic anemia, as well as the available treatments. For instance, NORD - National Organization for Rare Disorders, Inc., the Aplastic Anemia and MDS International Foundation, and CancerIndex sponsor awareness campaigns regarding aplastic anemia. February 2019 saw the launch of the Aplastic Anemia Trust's awareness campaign 'I'm Fantastic Not Aplastic'. As a result, more people will be aware of the condition, leading to increased diagnosis and treatment, thus driving the growth of the aplastic anemia treatment market.

• Increased Use Of Blood Transfusion Therapy To Treat Diseases - Blood transfusion therapy has been used for decades to treat aplastic anemia, and it is expected to become even more popular in the coming years as medical technology advances and more effective treatments become available. According to WHO, blood transfusions are most frequently performed on patients over 65 in high-income countries, accounting for 76% of all transfusions.
• Growing Number Of Bone Marrow Diseases - Aplastic Anemia is a serious condition caused by a lack of healthy blood cells in the body. Bone marrow diseases, such as leukemia and myelodysplastic syndromes, can cause the marrow to produce too few healthy blood cells, leading to aplastic anemia. As the number of these diseases increases, the demand for treatments, such as bone marrow transplants, is expected to grow. In the United States, approximately 18,000 people receive bone marrow transplants from related or unrelated matched donors each year for life-threatening illnesses.  
• Improved Healthcare Infrastructure, And The Growing Popularity of Health Insurance Schemes - With improved healthcare infrastructure, access to specialized treatments for aplastic anemia is becoming easier. People are also more inclined to invest in health insurance plans to cover the costs of treatments. It was observed that over 500 million people in India were covered under health insurance schemes in the fiscal year of 2021, and that number is expected to rise.
• A Rise In The Prevalence Of Non-Hodgkin Lymphoma Cases - Approximately 80,550 people (44,880 males and 35,670 females) will be diagnosed with non-Hodgkin lymphoma in 2023, according to the American Cancer Society. The number of deaths from this cancer includes both adults and children, with 11,780 men and 8,400 women affected.

Challenges

• Side effects associated with the medications used to treat the condition - The side effects of the drugs used to treat aplastic anemia can include nausea, vomiting, hair loss, dizziness, irregular heartbeat, and even liver damage. These side effects can make patients reluctant to take the medication, which can limit the effectiveness of the treatment.

• High cost of treatment

• Limited availability of donor stem cells